SCHEMBL4868466

SCHEMBL4868466

Cc1cc(NC(=O)N2CCCCc3ccccc32)ccc1O

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.69
NPC1 O15118 2/20 0.69
NFKB1 P19838 2/20 0.69
RAB9A P51151 2/20 0.69
NFKB2 Q00653 2/20 0.69
RELA Q04206 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
PKM P14618 1/20 0.69
LMNA P02545 5/20 0.64
TP53 P04637 2/20 0.64
POLB P06746 4/20 0.62
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
HTT P42858 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPK1 P28482 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
THRB P10828 1/20 0.56
ATM Q13315 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860681 0.87 MAPT (0.53) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4870679 0.86 TP53 (0.67) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4868982 0.86 MEN1 (0.60) MAPTNPC1NFKB1RAB9ANFKB2
Hydrochloric Acid SCHEMBL4863741 0.85 MEN1 (0.59) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4867127 0.84 MAPT (0.56) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4872378 0.84 MAPT (0.68) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4863126 0.84 POLB (0.83) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL14089574 0.83 LMNA (0.71) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4863076 0.83 MAPT (0.69) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4868320 0.82 ATM (0.66) MAPTNPC1NFKB1RAB9ANFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885NPC1 630/4885NFKB1 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.